We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Respiratory virus cell

A Respiratory Season Update

In recent past respiratory seasons, the world witnessed a “tripledemic” of Influenza (flu), SARS-CoV-2 (COVID-19), and Respiratory Syncytial Virus (RSV). The 2024-25 landscape will likely be different, with new virus variants, new vaccines and treatments, like the game-changing antibody that protects children from RSV. The healthcare and public health community have also learned some valuable lessons going forward with the ever-evolving respiratory agents.

In this presentation, Dr. Rodney Rohde will discuss the primary microbiology, epidemiology, control, prevention, vulnerable populations, the importance of laboratory validation and the benefits of molecular-based testing of these three primary respiratory season pathogens.  

In this comprehensive session, Dr. Rohde will:
  • Describe SARS-CoV-2, Influenza (flu), and RSV history, epidemiology and background
  • Summarize the risk factors and vulnerable patient populations for these pathogens
  • Describe the upcoming 2024-2025 respiratory season in the United States and Europe
  • Explain the importance of validation for laboratories prior to the respiratory season and the benefits of molecular testing
Rodney Rohde, PhD
Rodney Rohde, PhD
Regents’ Professor and University Distinguished Chair
Texas State University
Brought to you by
Register for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar